An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders

Summary

The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole monotherapy in the treatment of children and adolescents suffering from Autism Spectrum Disorder (ASD) over a 12-week period. We hypothesize that aripiprazole may be helpful in reducing ASD-associated symptoms of anxiety and aggression, resulting in significant improvements in global outcome.

Timeline

Start

2006-02

Primary completion

2008-12

Completion

2009-02

Drugs

Indications